ÀÓ¼±¹Î
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : Æó¾Ï, À¯¹æ¾Ï, °©»ó¼±¾Ï, ÇǺξÏ, Èñ±Í¾Ï
Á÷
ˤ
: Á¶±³¼ö
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
41
ÇØ¿Ü
Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboing ROS1 rearrangement
40
ÇØ¿Ü
Establishment of a conditional transgenic mouse model recapitulating EML4-ALK-positive human non-small-cell lung cancer
39
ÇØ¿Ü
Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients
38
ÇØ¿Ü
Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma
37
ÇØ¿Ü
Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
36
ÇØ¿Ü
ER2, a novel human anti-EGFR monoclonal antibody inhibit tumoractivity in non-small cell lung cancer models
35
ÇØ¿Ü
Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard
34
ÇØ¿Ü
Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy
33
ÇØ¿Ü
Prognostic Value of Volumetric Parameters on Staging and Posttreatment FDG PET/CT in Patients With Stage IV Non–Small Cell Lung Cancer
32
ÇØ¿Ü
A randomized phase II trial of ERCC1 and RRM1 mRNA expression‑based chemotherapy versus docetaxel/carboplatin in advanced non‑small cell lung cancer
1
2
3
4
5
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729